US FDA Type C Statistical Methods Meeting Granted to Review 2.5-Year OS Data for OST-HER2 in Metastatic Osteosarcoma
“We expect this Type C Statistics Methods Meeting with FDA to focus on the appropriateness of using pooled non-concurrent published historical control data, as compared with concurrent natural history data generated via OST-400, to evaluate the clinical efficacy data generated from the OST-HER2 Metastatic Osteosarcoma Trial,” said Dr. Craig Eagle, Chief Medical Advisor and member of the OS Therapies Board of Directors. “We are heartened that overall survival at the 2.5-year timepoint remained unchanged from the 2-year timepoint. We look forward to the interim 3-year overall survival data in early September 2026, that will allow for decisions on our pending Regenerative Medicine Advanced Therapy (RMAT) designation submission, FDA Rolling Review and Commissioner’s National Priority Review Voucher more rapidly to facilitate a potential Biologics License Application under the Accelerated Approval Program by year end 2026.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000